Recent progress on the topical therapy of onychomycosis

Expert Opinion on Investigational Drugs

Volumn 16, Issue 2, 2007, Pages 157-167

  Alley, Michael R K ^a   Baker, Stephen J ^a   Beutner, Karl R ^a   Plattner, Jacob ^a  

^a PFIZER INC   (United States)

Author keywords

Antifungal agent; Dermatophyte; Fungal infection; Leucyl tRNA synthetase; Nail penetration; Onychomycosis; Oxaborole; Tinea unguium

Indexed keywords

2 AMINOCYCLOPENTANECARBOXYLIC ACID; ABAFUNGIN; ABASOL; ALCOHOL; AMOROLFINE; AN 2690; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BUTENAFINE; CICLOPIROX; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; HYPHANOX; ICOFUNGIPEN; ITRACONAZOLE; MACROGOL; NAFTIFINE; NM 100060; ONYCOFITEX; PSEUDOMONIC ACID; S 291ND; TERBINAFINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DERMATOPHYTE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; HUMAN; INCIDENCE; LIVER INJURY; LIVER TOXICITY; ONYCHOMYCOSIS; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TINEA CAPITIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; ONYCHOMYCOSIS;

EID: 33846782897     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.2.157     Document Type: Review

References (52)

1. GHANNOUM MA, HAJJEH RA, SCHER R et al.: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J. Am. Acad. Dermatol. (2000) 43(4):641-648.
2. ELEWSKI B, CHARIF MA: Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch. Dermatol. (1997) 133:1172-1173.
3. HOSSAIN MA, GHANNOUM MA: New developments in chemotherapy for non-invasive fungal infections. Expert Opin. Investig. Drugs (2001) 10(8):1501-1511.
4. GUPTA AK, JAIN HC, LYNDE CW et al.: Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. (2000) 43:244-248.
5. SHEAR NH, GUPTA AK: Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails. Arch. Dermatol. (1995) 131:937-942.
6. HABIF TB: Nail diseases. In: Clinical dermatology. Chapter 25, Habif TB (Ed.), Mosby, Inc., Philadelphia, USA (2004) 4:875.
7. SCHER RK, BARAN R: Onychomycosis in clinical practice: factors contributing to recurrence. Br. J. Dermatol. (2003) 149(Suppl. 65):5-9.
8. ARRESE JE, PIÉRARD GE: Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology (2003) 207:255-260.
9. GUPTA AK, LYNCH LE: Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. Cutis (2004) 74(Suppl. 1):10-15.
10. TOSTI A, PIRACCINI BM, STINCHI C et al.: Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology (1998) 197:162-166.
11. MURDAN S: Drug delivery to the nail following topical application. Int. J. Pharm. (2002) 236:1-26.
12. GUPCHUP GV, ZATZ JL: Structural characteristics and permeability properties of the human nail: a review. J. Cosmet. Sci. (1999) 50:363-385.
13. STÜTTGEN G, BAUER E: Bioavailability, skin- and nail penetration of topically applied antimycotics. Mykosen (1982) 25:74-80.
14. HANEKE E: Fungal infections of the nail. Semin. Dermatol. (1991) 10:41-53.
15. MERTIN D, LIPPOLD BC: In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maximum flux. J. Pharm. Pharmacol. (1997) 49:30-34.
16. WALTERS KA, FLYNN G L, MARVEL JR: Physiochemical chemical characterization of the human nail: permeation pattern for water and the homologous alcohols and the difference with respect to stratum corneum. J. Pharm. Pharmacol. (1983) 35:28-33.
17. KOBAYASHI Y, MIYAMOTO M, SUGIBAYASHI K et al.: Drug permeation through the three layers ofthe human nail plate. J. Pharm. Pharmacol. (1999) 51:271-278.
18. SIGURGEIRSSON B, BILLSTEIN S, RANTANEN T et al.: L.I.O.N. study: efficacy and tolerability of continuous terbinafine (Lamisil®) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Br. J. Dermatol. (1999) 141(Suppl. 56):5-14.
19. DE CUYPER C, HINDRYCKX PH: Long-term outcomes in the treatment of toenail onychomycosis. Br. J. Dermatol. (1999) 141(Suppl. 56):15-20.
20. GHANNOUM MA, RICE LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. (1999) 12:501-517.
21. DE BACKER M, DE KEYSER P, DE VROEY C et al.: A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day versus itraconazole 200 mg/day - a double blind comparative trial. Br. J. Dermatol. (1996) 134(Suppl. 46):16-17.
22. BARAN R, GUPTA AK, PIÉRARD GE: Pharmacology of onychomycosis. Expert Opin. Pharmacother. (2005) 6(4):609-624.
23. RICHARDSON MD, WARNOCK DW: In: Fungal infections, diagnosis and management. Third Edition, Blackwell Publishing, Malden, USA (2003).
24. WEINBERG ED: Antifiangal agents. In: Principles of medicial chemistry. Chapter 35, Foye WO (Ed.), Leo & Febiger, Malvern, USA (1990) 3:731.
25. GULL K, TRINCI AP: Griseofulvin inhibits fungal mitosis. Nature (1973) 244:292-294.
26. GUPTA AK: Ciclopirox: an overview. Int. J. Dermatol. (2001) 40:305-310.
27. GUPTA AK, PLOTT T. Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. Int. J. Dermatol. (2004) 43(Suppl. 1):3-8.
28. POLAK A: Mode of action of morpholine derivatives. Ann. NY Acad Sci. (1988) 544:221-228.
29. FANG FC: Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. (1997) 99(12):2818-2825.
30. BAKER SJ, ZHANG YK, AKAMA T et al.: Discovery of a new boron-containing anti-fungal agent, 5-fluoro-1,3-dihydro- 1-hydroxy-2, 1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J. Med. Chem. (2006) 49:4447-4450.
31. GUPTA AK, RYDER JE, BARAN R: The use of topical therapies to treat onychomycosis. Dermatol. Clin. (2003) 21:481-489.
32. ROBERTS DT: Onychomycosis: current treatment and future challenges. Br. J. Dermatol. (1999) 141 (Suppl. 56):1-4.
33. BAKER SJ, HUI X, MAIBACH HI: Progress on new therapeutics for fungal nail infections. Ann. Rep. Med. Chem. (2005) 40:323-334.
34. KOBAYASHI Y. KOMATSU T, SUMI M et al.: In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur. J. Pharm. Sci. (2004) 21:471-477.
35. TATSUMI Y, YOKOO M, SENDA H et al. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob. Agents Chemother. (2002) 46:3797-3801.
36. HUI X, CHAN TCK, BARBADILLO S et al.: Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J. Pharm. Sci. (2003) 92:142-148.
37. HUI X, BAKER SJ, WESTER RC et al.: In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J. Pharm. Sci. (2006) (In Press).
38. COLOMBO B, FELICETTI L, BAGLIONI C: Inhibition of protein synthesis by cycloheximide in rabbit reticulocytes. Biochem. Biophys. Res. Commun. (1965) 18:389-395.
39. GROLLMAN AP: Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J. Biol. Chem. (1967) 242(13):3226-3233.
40. JUSTICE MC, HSU MJ, TSE B et al: Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis. J. Biol. Chem. (1998) 273(6):3148-3151.
41. FULLER AT, MELLOWS G, WOOLFORD M et al.: Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature (1971) 234(5329):416-417.
42. NICHOLAS RO, BERRY V, HUNTER PA et al.: The antifungal activity of mupirocin. J. Antimicrob. Chemother. (1999) 43(4):579-582.
43. PETRAITIS V, PETRAITIENE R, KELAHER AM et al.: Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Antimicrob. Agents Chemother. (2004) 48(10):3959-3967.
44. ZIEGELBAUER K: Decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance to the cyclic β-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. (1998) 42(7):1581-1586.
45. ZIEGELBAUER K, BABCZINSKI P, SCHONFELD W. Molecular mode of action of the antifungal β-amino acid BAY 10-8888. Antinticrob. Agents Chemother. (1998) 42(9):2197-2205.
46. CAPOBIANCO JO, ZAKULA D, COEN ML et al.: Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action. Biochem. Biophys. Res. Commun. (1993) 190(3):1037-1044.
47. HENDRICKSON TL, SCHIMMEL P: Transfer RNA-dependent ainino acid discrimination by aminoacyl-tRNA synthetase. In: Translation mechanisms. Lapointe JPD, Brakier-Gingras L (Eds), Landes Bioscience, Georgetown, USA (2003):34-64.
48. CUSACK S, YAREMCHUK A, TUKALO M: The 2 Å crystal structure of leucyl-tRNA synthetase and its complex with a leucyl-adenylate analogue. EMBO J. (2000) 19(10):2351-2361.
49. FUKAI S, NUREKI O, SEKINE S et al.: Structural basis for double-sieve discrimination of L-valine from L-isoleucine and L-threonine by the complex of tRNA(Val) and valyl-tRNA synthetase. Cell (2000) 103(5):793-803.
50. NUREKI O, VASSYLYEV DG, TATENO M et al.: Enzyme structure with two catalytic sites for double-sieve selection of substrate. Science (1998) 280(5363):578-582.
51. HUGHES J, MELLOWS G: Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase. Biochem. J. (1980) 191(1):209-219.
52. SILVIAN LF, WANG J, STEITZ TA: Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. Science (1999) 285(5430):1074-1077.